O meio RPMI 1640 foi desenvolvido no Instituto Roswell Park Memorial, em 1966, por Moore e seus colaboradores. Uma modificação do meio 5A de McCoy. Ele foi formulado para dar suporte a células linfoblastoides em cultura de suspensão, mas desde então demonstrou ser capaz de fornecer suporte a uma ampla gama de células dependentes de ancoragem. Destinado originalmente para ser usado com um suplemento de soro, demonstrou-se que o RPMI 1640 dá suporte a diversas linhagens celulares na ausência de soro. Ele também foi usado amplamente nos protocolos de fusão e no crescimento de células híbridas. Esse meio é adequado para a cultura de leucócitos humanos normais e neoplásicos.
Outras notas
This RPMI-1640 medium is supplemented with L-Ala-L-Gln dipeptide. This provides a more stable form of glutamine for cell culture. Free amino acid L-glutamine is known to be unstable in cell culture.
Informações legais
StableCell is a trademark of Sigma-Aldrich Co. LLC
International journal of molecular sciences, 22(6) (2021-04-04)
A high platelet count is associated with a poor prognosis in ovarian cancer (OvCa). Despite good clinical responses with platinating agents in combination with taxanes, numerous OvCa patients relapse due to chemotherapy resistance. Here, we report that treatment of OvCa
microRNA (miRNA) dysregulation is a common feature of cancer cells, but the complex roles of miRNAs in cancer are not fully elucidated. Here, we used functional genomics to identify oncogenic miRNAs in non-small cell lung cancer and evaluate their impact
Hepatocellular carcinoma (HCC) is a deadly form of liver cancer with high mortality worldwide. Unfortunately, the large heterogeneity of this disease makes it difficult to develop effective treatment strategies. Cellular network analyses have been employed to study heterogeneity in cancer
Perturbation in JAK-STAT signaling has been reported in the pathogenesis of cutaneous T cell lymphoma (CTCL). JAK3 is predominantly associated with the intra-cytoplasmic part of IL-2Rγc located in the plasma membrane of hematopoietic cells. Here we demonstrate that JAK3 is
Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be used to recruit albumin. A prerequisite for such design is that
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
